Volume 22 (2023)
Volume 21 (2022)
Volume 20 (2021)
Volume 19 (2020)
Volume 18 (2019)
Volume 17 (2018)
Volume 16 (2017)
Volume 15 (2016)
Volume 14 (2015)
Volume 13 (2014)
Volume 12 (2013)
Volume 11 (2012)
Volume 10 (2011)
Evaluation of glucose-6-phosphate dehydrogenase serum level in patients with multiple sclerosis and neuromyelitis optica

Niloofar Chitsaz; Leila Dehghani; Amir Safi; Nazgol Esmalian-Afyouni; Vahid Shaygannejad; Majid Rezvani; Karim Sohrabi; Kaykhosro Moridi; Milad Moayednia

Volume 18, Issue 4 , December 2019, , Pages 150-153

  Background: Multiple sclerosis (MS) and neuromyelitis optica (NMO) are both demyelinating disorders and oxidative stress is suggested to have a role in their pathogenesis. Glucose-6-phosphate dehydrogenase (G6PD) produces nicotinamide adenine dinucleotide phosphate (NADPH) via the pentose phosphate pathway. ...  Read More

Polymorphisms at activated protein C cleavage sites of factor V: Are they important in the absence of factor V Leiden?

Ehsan Kheradmand; Shaghayegh Haghjooy-Javanmard; Leila Dehghani

Volume 16, Issue 1 , January 2017, , Pages 30-33

  Background: Activated protein C (APC) inactivates factor V (FV) by cleavage of its heavy chain at Arg306, Arg506, Arg679, and Lys994. Mutational changes, which abolish APC cleavage sites, may predispose thrombosis by altering the inactivation process of FV. FV Leiden (FVL) (Arg506Glu) has been demonstrated ...  Read More

Neurological manifestations in patients with antiphospholipid syndrome.

Masoud Etemadifar; Leila Dehghani; Soheil Tahani; Nafiseh Toghianifar; Marzieh Rahaimi; Nahid Eskandari

Volume 12, Issue 4 , December 2013, , Pages 172-175

  Background: Anti-phospholipids syndrome (APS) is considered a non inflammatory auto-immune disease with a significant thrombophilic risk with varied clinical manifestations. The purpose of the current study was to investigate the frequency of thrombotic and non-thrombotic events in patients with APS.Methods: ...  Read More